Clinical Trials
98 trialsNCT07602907 2026-05-22
Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07597629 2026-05-19
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2 Not yet recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT07591090 2026-05-15
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Akeso
Phase 2 Not yet recruiting
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT05831878 2026-05-13
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT06638307 2026-05-12
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT07540533 2026-04-20
2025-370
Henan Cancer Hospital
Phase 2 Recruiting
NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT05424068 2026-02-25
Rehabilitation for People With Advanced Cancer
University Health Network, Toronto
Phase NA Completed
NCT07428655 2026-02-24
Acceptability and Feasibility of PSC Model of Serious Illness Communication
National Cancer Centre, Singapore
Phase NA Active not recruiting
NCT07427394 2026-02-23
SERENA-1b
AstraZeneca
Phase 2 Not yet recruiting
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT07259226 2025-12-02
OASIS
UNICANCER
Phase 2 Recruiting
NCT05530057 2025-11-20
ESPERO
Seoul National University Hospital
Phase 2 Recruiting
NCT07130383 2025-11-18
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2 Recruiting
NCT07180082 2025-11-18
CORIN-PYRA
RenJi Hospital
Phase 2 Recruiting
NCT07180160 2025-11-18
ITHRAN
RenJi Hospital
Phase 2 Recruiting
NCT07173556 2025-09-15
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05876065 2025-09-11
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT07125950 2025-08-15
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07101601 2025-08-03
Study of DM5167 in Patients With Advanced Solid Tumors
DIGMBIO
Phase 1 Recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07041437 2025-06-27
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting
NCT05536128 2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2 Recruiting
NCT06710990 2025-03-28
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06750848 2024-12-27
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Phase 2 Not yet recruiting
NCT06470672 2024-12-20
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Unknown
NCT06656624 2024-10-24
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT06176534 2024-08-20
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase â…¡ Clinical Trial
Henan Cancer Hospital
Phase 2 Recruiting
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT06433609 2024-05-30
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Beijing GoBroad Hospital
Phase 2 Not yet recruiting
NCT06339281 2024-04-19
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06375707 2024-04-19
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT06125834 2024-04-16
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06354114 2024-04-09
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT05861830 2024-03-12
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Peking Union Medical College Hospital
Phase 3 Recruiting
NCT06290466 2024-03-04
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects
Ahon Pharmaceutical Co., Ltd.
Phase 1 Completed